Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jul 11;119(27-28):488-489.
doi: 10.3238/arztebl.m2022.0171.

The Willingness to Participate in Pediatric Type 1 Diabetes Studies

Sophie Heinke, Angela Hommel, Anja Loff, Reinhard Berner, Ezio Bonifacio  1
Affiliations

The Willingness to Participate in Pediatric Type 1 Diabetes Studies

Sophie Heinke et al. Dtsch Arztebl Int. .
No abstract available

PubMed Disclaimer

Figures

Figure
Figure
Willingness to participate in the Freder1k and POInT study in Saxony and Thuringia between 2017 and 2021; 471 children at increased risk for type 1 diabetes. 317 of the 471 families invited took up the offer of an initial consultation in the study center (“screening visit“, SV). Of these 317, 151 subsequently participated in the intervention study POInT. *All Freder1k invitations were reported back only until 6/2020, from 7/2020 to 11/2021 only positive results were reported back. For this reason, the consent rate in this time period cannot be determined with any certainty.
See this image and copyright information in PMC

References

    1. Bonifacio E, Beyerlein A, Hippich M, et al. Genetic scores to stratify risk of developing multiple islet autoantibodies and type 1 diabetes: a prospective study in children. PLoS Med. 2018;15 e1002548. - PMC - PubMed
    1. Winkler C, Haupt F, Heigermoser M, et al. Identification of infants with increased type 1 diabetes genetic risk for enrollment into primary prevention trials-GPPAD-02 study design and first results. Pediatr Diabetes. 2019;20:720–727. - PMC - PubMed
    1. Ziegler AG, Danne T, Dunger DB, et al. Primary prevention of beta-cell autoimmunity and type 1 diabetes - the global platform for the prevention of autoimmune diabetes (GPPAD) perspectives. Mol Metab. 2016;5:255–262. - PMC - PubMed
    1. Ziegler AG, Achenbach P, Berner R, et al. Oral insulin therapy for primary prevention of type 1 diabetes in infants with high genetic risk: the GPPAD-POInT (global platform for the prevention of autoimmune diabetes primary oral insulin trial) study protocol. BMJ Open. 2019;9 e028578. - PMC - PubMed
    1. Ziegler AG, Arnolds S, Kölln A, et al. Supplementation with Bifidobacterium longum subspecies infantis EVC001 for mitigation of type 1 diabetes autoimmunity: the GPPAD-SINT1A randomised controlled trial protocol. BMJ Open. 2021;11 e052449. - PMC - PubMed